Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-Peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men

J. D. Veldhuis, M. Bidlingmaier, S. M. Anderson, Z. Wu, C. J. Strasburger

Research output: Contribution to journalArticlepeer-review

70 Scopus citations

Fingerprint Dive into the research topics of 'Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-Peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds